Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys

Jes Gerlach, Daniel E. Casey

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


1. 1. Nine Cebus monkeys, 6 with mild spontaneous oral dyskinesia (tongue protrusions), were tested with two dopamine D2 antagonists, remoxipride (a new substituted benzamide) and haloperidol, and witn two dopamine agonists, methylphenidate and apomorphine. 2. 2. Remoxipride 4 and 8 mg kg and haloperidol 0.01 and 0.02 mg kg given alone induced identical dystonic-dyskinetic syndromes. 3. 3. Methylphenidate 0.5 mg kg caused increased arousal, but reduced oral dyskinesia, while apomorphine 0.25 mg kg slightly increased arousal and induced/aggravated oral dyskinesia. 4. 4. Remoxipride 2 and 4 mg kg and haloperidol 0.005 and 0.01 mg kg equally antagonized the methylphenidate- and apomorphine-induced arousal, but not oral dyskinesia. 5. 5. Marked sedation was seen when apomorphine was given together with either D2 receptor antagonists. 6. 6. It is concluded that remoxipride and haloperidol have a similar qualitative effect in motor behavior in Cebus monkeys, but the quantitative difference between the dystonia-inducing dose levels of the two drugs compared with the antipsychotic dose levels (estimated from clinical studies) suggests that remoxipride may cause relatively few extrapyramidal side-effects in human.

Original languageEnglish (US)
Pages (from-to)103-112
Number of pages10
JournalProgress in Neuropsychopharmacology and Biological Psychiatry
Issue number1
StatePublished - 1990


  • apomorphine
  • arousal
  • dyskinesia
  • dystonia
  • haloperidol
  • methylphenidate
  • monkey
  • remoxipride

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry


Dive into the research topics of 'Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys'. Together they form a unique fingerprint.

Cite this